AbsTrACT
Objective timely diagnosis and management of heart failure (hF) is critical, but identification of patients with suspected hF can be challenging, especially in primary care. We describe the journey of people with hF in primary care from presentation through to diagnosis and initial management. Methods We used the clinical Practice research Datalink (primary care consultations linked to hospital admissions data and national death registrations for patients registered with participating primary care practices in england) to describe investigation and referral pathways followed by patients from first presentation with relevant symptoms to hF diagnosis, particularly alignment with recommendations of the national institute for health and care excellence guideline for hF diagnosis. results 36 748 patients had a diagnosis of hF recorded that met the inclusion criteria between 1 January 2010 and 31 March 2013. For 29 113 (79.2%) patients, this was first recorded in hospital. in the 5 years prior to diagnosis, 15 057 patients (41.0%) had a primary care consultation with one of three key hF symptoms recorded, 17 724 (48.2%) attended for another reason and 3967 (10.8%) did not see their general practitioner. Only 24% of those with recorded hF symptoms followed a pathway aligned with guidelines (echocardiogram and/or serum natriuretic peptide test and specialist referral), while 44% had no echocardiogram, natriuretic peptide test or referral. Conclusions Patients follow various pathways to the diagnosis of hF. however, few appear to follow a pathway supported by guidelines for investigation and referral. there are likely to be missed opportunities for earlier hF diagnosis in primary care.
InTrOduCTIOn
In heart failure (HF), accumulation of fluid in lungs and peripheries and reduction in blood flow to the muscles result in classic symptoms of breathlessness, ankle swelling and fatigue.
1 HF has considerable impact on patients and healthcare systems, 2 with high morbidity and mortality. 3 The Global Burden of Disease study estimated that some 40 million people had HF worldwide in 2015 4 ; the estimated UK total is 550 000.
5
Early identification is key to effective management. 1 Professionals rely initially on symptom recognition; the use of serum natriuretic peptide (either B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NTproBNP)) as a screening test in symptomatic patients has been recommended for over 10 years. [6] [7] [8] Patients with HF often present first in primary care. 9 Identification and diagnosis in primary care is supported by professional guidelines 1 8 10 recommending minimum standards of investigation, 11 as well as medications improving symptoms and prognosis (beta-blockers and ACE inhibitors). In the National Health Service (NHS) in England, some elements of investigation and management in primary care (echocardiographic imaging, referral for 'specialist assessment', referral for exercise-based rehabilitation and treatment with an ACE inhibitor or angiotensin II receptor blocker (ARB) and a beta-blocker) have for over 10 years been supported by performance related payments under an incentivisation scheme-the Quality and Outcomes Framework.
National Institute for Health and Care Excellence (NICE) guidance recommends the following for patients presenting with HF symptoms in primary care 8 : 1. history and examination 2. for patients with history of acute myocardial infarction (AMI): referral for echocardiograph and 'specialist' assessment, usually by a consultant cardiologist or HF nurse specialist, for confirmation of diagnosis, classification and planning of management, within 2 weeks 3. for patients without history of AMI: serum natriuretic peptide and ECG, followed by echocardiograph and referral for specialist assessment within 6 weeks subject to a BNP level of 100-400 pg/mL or NTproBNP 400-2000 pg/ mL (patients with higher levels, BNP >400 pg/ mL or NTproBNP >2000 pg/mL, require referral within 2 weeks). Diagnosis and management of HF in primary care has been criticised, with evidence of both underdiagnosis 12 13 and overdiagnosis, 14 and no improvement in survival over nearly 15 years. 15 Professionals may fail to adhere to guidance and lack confidence in investigations and treatments. 12 16 17 This has changed little, despite new guidance and incentivisation. 15 16 18 However, a clear picture of identification and management pathways for HF in primary care is currently lacking. Using linked primary and secondary care routinely collected data, we sought to characterise the journey of patients with HF symptoms in NHS primary care in England through investigation, treatment and referral, assessing potential for earlier diagnosis.
MeTHOds data sources
The Clinical Practice Research Datalink (CPRD) is a database of pseudonymised electronic records from about 7% of UK general practices from 1987 to the present, considered representative of the UK population. 19 Primary care records are linked nationally to hospital admissions (Hospital Episode Statistics (HES)) and the death registry (Office for National Statistics (ONS)).
Patient cohort and subgroups
We searched for patients with HF diagnosed between 1 January 2010 and 31 March 2013. For each patient, diagnosis date was the first coded record of HF, either in the primary care record or in hospital admission data. We identified primary care consultations and hospital admissions for HF using codes by Hawkins et al 20 augmented by our local clinicians (see online appendix). In HES, the earliest record of HF in International Statistical Classification of Diseases, 10th revision, codes, recorded as either primary or secondary diagnoses, was used.
The following exclusion criteria applied: CPRD records at practices not linked to HES, patients not registered in a CPRD practice for the whole 10-year period and standard CPRD data quality exclusions regarding 'up to standard' practices and patients with 'acceptable data quality' (see online appendix).
Published sets of clinical codes for patient characteristics, tests, medications and referrals were used whenever available (see online appendix), tracking back 5 years before the date of diagnosis. For example, comorbidities from the Charlson set were defined as per Khan et al, 21 with some extra comorbidities defined by our team. Otherwise, codes were identified using the CPRD medical and product dictionaries.
Pathway definitions
We divided patients into two main groups according to primary care consultations in the 5 years before HF diagnosis: those with a primary care record of HF symptoms and those with a primary care consultation but no recorded HF symptoms.
In the first group, we classified management into seven 'pathways' depending on tests, medications and referrals recorded. Pathway #1 comprised patients investigated in accordance with NICE recommendations (echocardiogram and/or serum natriuretic peptide test and a referral to a specialist): we refer to this as the 'NICE recommended pathway' as a shorthand, although for the most part we did not incorporate the guideline's timeframe. Partial concordance with guidelines was defined as pathway #2 (echocardiogram and/or serum natriuretic peptide test but no referral) or pathway #4 (referral only). Patients who had no investigations recorded but were on appropriate medications for HF were categorised as pathway #3a (put on a new type of medication) or pathway #3b (already on medication). Medications of interest were ACE inhibitors, ARBs and HF-specific beta-blockers. Pathway #5 ('Other pathway') covered those who had received other relevant management options, such as smoking cessation advice, influenza vaccination, an ECG and/or a non HF-specific betablocker. Finally, pathway #6 ('No pathway followed') covered patients with recorded symptom(s) who did not appear to receive any management.
For the second group, who saw their general practitioner (GP) but had no record of HF symptoms, the same set of pathways was applied using consultation records in the 5 years before HF diagnosis.
statistical analysis
Patient characteristics were summarised for all patients, while comorbidities were examined for those presenting to their GP with an HF symptom before diagnosis. Data were reported as absolute numbers and proportions with p values from χ 2 tests. Analyses were conducted using SAS V.9.4.
resulTs

Patient characteristics
Between 1 January 2010 and 31 March 2013, 36 748 patients had a diagnosis of HF recorded in CPRD practices that met the inclusion criteria and were included in the analysis. A total of 29 113 (79.2%) had this first recorded in hospital data (HES) and 7635 (20.8%) in primary care. Half were female and nearly one in three was aged 85 or over; 9 in 10 had at least one potentially relevant comorbidity, with nearly half having three or more, especially hypertension (69.9%), chronic pulmonary disease (33.9%) and coronary artery disease (31.6%) (table 1).
A total of 15 057 patients (41.0%) had a primary care consultation with one of the three HF symptoms recorded before diagnosis (table 2) , while 21% presented with any two and just 2% presented with all three. The most common symptom was breathlessness, present in 80% of the 15 057. Half had a primary care consultation prediagnosis but with some other symptom recorded, and the remaining 11% had no primary care consultation prior to diagnosis. Figures 1 and 2 show patients in each of the two main groups split by the elements of the NICE-recommended pathway; table 3 provides more detail on their management. The remaining 3967 patients had no contact with primary care in the 5 years before diagnosis and were hospitalised for HF, giving this hospital admission date as the date of their diagnosis. We did not consider them further in the analysis.
In addition to categorising patients based on HF symptom recorded in primary care, we also examined whether HF was first recorded in primary or secondary care; we use 'GP-diagnosed' and 'hospital-diagnosed' as shorthand for this. One in five patients were GP diagnosed, of whom almost all (97%) had seen the GP for some reason in the previous year and just over half (55%) had presented with HF symptoms in the previous 5 years. Nearly four in five patients were hospital diagnosed, of whom most (89%) had seen the GP for some reason in the previous year and a third (37%) had an HF symptom recorded in a GP consultation in the previous 5 years.
Patients with a record of HF symptoms in a primary care consultation
Nearly one in four (23.6%) of the 15 057 patients with HF symptoms recorded before diagnosis followed the NICE-recommended pathway (#1) of an echocardiogram and/or serum natriuretic peptide test and a specialist referral; another 14.4% were referred without either investigation ( figure 1,  table 3 ). GP-diagnosed patients were more than twice as likely to be on the NICE-recommended pathway (#1) than hospital-diagnosed ones. Of those not referred for any element of the NICE pathway, 3705 (=926+2779) or a quarter of this group were already taking or started relevant medication Heart failure and cardiomyopathies (pathways #3a and #3b) on presentation of HF symptoms. In the 9% of this group on no pathway, subsequent hospital diagnosis was much more likely than GP diagnosis.
Considering adherence to NICE recommended timeframes, 1991 (13.2% of the 15 057) had had a previous AMI at the time of their first symptom, of whom only 23 (1.2%) completed the pathway within the recommended 2 weeks. A total of 13 066 (86.8% of the 15 057) had not had a previous MI at the time of their first symptom, of whom 511 (3.9%) completed the pathway within the recommended 6 weeks. 
Patients with only a record of non-HF symptoms in a primary care consultation
Nearly one in eight (13.2%) of the 17 724 with only non-HF symptoms recorded in primary care before diagnosis followed the NICE-recommended pathway (#1); another 12.5% were referred without recorded investigation ( figure 2, table 3 ). Of those 3922 (=1606+134+1918+264 from figure 2) patients referred for an echo without recorded HF symptoms, 1461 (37%) had circulatory disorders recorded at the consultation at which the referral was made, including 786 (20%) that were actually HF. One in four of this group followed no pathway: again, subsequent hospital diagnosis was much more likely than GP diagnosis.
dIsCussIOn summary of findings
Patients took many routes to a HF diagnosis. Only one in five patients with recognised HF had it first recorded in a primary care consultation, although almost all of them had seen a GP in the year before this diagnosis date, almost half with recorded HF symptoms. The remaining four out of five patients had HF recorded for the first time during a hospital admission; the vast majority of these had also seen a GP in the previous year, 37% with recorded HF symptoms. In the 5 years before diagnosis, only 11% had no primary care consultation. Of the 41% of our sample with a primary care consultation with one of the three key HF symptoms, management aligned with NICE guidance was documented for nearly one in four (pathway #1): only 4% followed it within 6 weeks. Another one in seven were referred without record of either investigation (pathway #4).
For the 48% of patients who had a primary care consultation with only non-HF symptoms recorded, the picture was also mixed. One in nine followed the NICE-recommended pathway, suggesting that the GP suspected HF but did not record an HF symptom. This is supported by the fact that HF was recorded as a diagnosis for 20% of these patients during the consultation when the referral was made.
Comparison with other studies
CPRD has recently been used to look at prognosis following HF diagnosis in primary care and secondary outpatient care. 22 Of nearly 78 000 patients identified with HF in primary or secondary care in that study between 1997 and 2010, 42% were first recorded in primary care and 58% on hospital admission. Our data, covering patients diagnosed between 2010 and 2013, suggest a more extreme differential of 21% and 79%. Inspection of our full CPRD extract dating back in 1997 reveals a steady rise in the proportion of patients diagnosed in hospital from about 50% in 2003 to about 80% in 2013. Reasons for this are unclear. It is possible that increasing familiarity with guidelines has led GPs to be cautious in diagnosing and treating HF in primary care based on clinical assessment: they may be more likely to await recommended investigations and specialist assessment. Pressure on secondary care diagnostic services may lead to some patients then presenting to hospital acutely while still under investigation. Patients admitted to hospital for HF without a prior diagnosis of HF in primary care have worse prognosis and management. 22 Much less is known about what happens before diagnosis, and ours is the first study to our knowledge mapping out the routes to a diagnosis of HF.
strengths
Almost 100% of England's population has access to primary and secondary care. The large data source provides sufficient sample size to describe the varied routes to a diagnosis of HF in real-world practice. The CPRD population is broadly representative of the UK population in terms of age, sex and ethnicity, and the database is well used in research. 19 HES covers all NHS hospitals in England with excellent coverage and highly accurate primary diagnosis and procedure coding. 23 The CPRD-HES-ONS linkage allows researchers to track patient pathways through the whole system, rare in other countries.
limitations
CPRD data are entered by GPs during routine consultations and not for the purpose of research. Their use allows auditing for clinical quality improvement and supports claims relating to financially incentivised activities. [24] [25] [26] Therefore, those required by schemes such as the UK's Quality and Outcomes Framework may be more likely to be used than, for example, Heart failure and cardiomyopathies symptom codes. 27 However, it is recognised that coding in primary care remains highly variable. 24 We divided our cohort based on recording of HF symptoms in GP consultations. The validity of this approach depends both on patients reporting symptoms and, more importantly, GPs recording them as Read codes; free text is no longer available in CPRD. We found a number of patients following the NICE HF pathway despite having none of the three main symptoms entered for that consultation. Instead, a variety of codes for procedures, examination and diagnoses were listed, with over half the patients having circulatory system disorders.
Another apparent anomaly is that 18% of patients referred for an echocardiogram actually had a diagnosis of HF recorded in the same consultation. Some GPs likely wished to code a working diagnosis while following the pathway for investigation. Of course, other GPs may wish to have the diagnosis confirmed by investigations before 'committing themselves' by entering the code for HF in the notes, leading to the variation we found.
As with many epidemiological studies, case designation relies primarily on physician diagnosis rather than objective investigations. While there is evidence of underdiagnosis, 28 a UK study that used an expert panel found that perhaps a third of patients may be incorrectly labelled as having HF. 16 Nevertheless, the working diagnosis is arguably the most relevant definition when examining prescribing behaviour. 20 Early identification and classification of HF is key to effective management, 1 with an important distinction to be made between patients who have HF with reduced ejection fraction, where conventional medical therapies are effective in improving outcomes, and HF with preserved ejection fraction, where they generally are not. 28 This distinction is generally not well made in primary care, 28 and relevant Read codes are rarely used. We were therefore unable to distinguish between the two.
Our definitions of the various pathways following GP consultation depended on several elements. Both referrals and echocardiograms may be made for other cardiac problems and are not necessarily specific for HF, but we have made the assumption that in our cohort, consisting of patients with HF recorded at some point, these were made for suspected HF. Serum natriuretic peptide testing was recommended in the 2005 European Society of Cardiology and the August 2010 NICE guidance but only available for a minority of practices during our study period. It is now more widely used, though threshold values are still under discussion. 9 
Implications for policy and practice
There are significant challenges in the identification, diagnosis and management of HF in primary care. 9 HF manifests itself in different ways, resulting in variation in patients' healthseeking behaviour and GPs' decision making. Sudden onset, severe symptoms will lead the patients straight to the emergency department, bypassing earlier diagnosis by the GP. In contrast, patients with more insidious symptoms of HF may not see their GP in the early stages but wait instead until symptoms worsen and then attend the emergency department, perhaps influenced by actual or perceived problems with GP access. Others may see their GP with several different problems and fail to mention HF symptoms until the GP's suspicions are at last raised.
From the GP's perspective, the diagnosis is made harder by the lack of specificity of HF symptoms and the confusion with respiratory conditions 12 (one in three of our cohorts had chronic obstructive pulmonary disease compared with just 2% for the general population 29 and 11% for patients aged 75-79), 30 limited time availability, limited access to investigations and low confidence in interpretation of investigation results. 9 While clear clinical guidelines exist, perceived information overload as well as a belief that they do not apply to all patients mean that GPs do not always use them 9 and not all will be aware of them. Our results suggest that NICE guidelines (currently being updated) are not followed in primary care for the majority of patients who go on to be diagnosed with HF, with a significant majority being diagnosed in the acute, secondary care setting. Finally, uncertainty about pharmacological management strategies, and concerns about comorbidity and polypharmacy, especially in elderly patients, 9 complicates initial management; long waiting lists and limited availability of serum natriuretic peptide testing and specialist clinics may also prove a disincentive to GPs in referring patients. 9   Table 3 Management pathways after first symptom*, overall and by diagnosis source Definitions of pathways: #1: echo and/or BNP and referral (NICE); #2: echo and/or BNP but no referral; #3a: no echo, BNP or referral but put on a new medication (ACEI/ARB/HF-BB); #3b: no echo, BNP or referral but already on a medication (ACEI/ARB/HF-BB); #4: referral only; #5: other pathway (had some kind of management, eg, given ECG/smoking advice/influenza jab and already on or put on a beta-blocker); #6: no pathway followed. p Value for χ 2 test of independence between the proportions in primary care and hospital patients were all significant at 0.001. *Where management came after the first symptomthat was recorded during the 5-year prediagnosis period (including the diagnosis date). †Management recorded during the 5-year prediagnosis period (including the diagnosis date). ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; BNP, B-type natriuretic peptide; HF, heart failure; HF-BB, HF-specific beta-blockers; NICE, National Institute for Health and Care Excellence.
